{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:15:42Z","timestamp":1792185342957,"version":"4.4.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,8]],"date-time":"2015-02-08T00:00:00Z","timestamp":1423353600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s12016-015-8466-y","type":"journal-article","created":{"date-parts":[[2015,2,7]],"date-time":"2015-02-07T06:20:20Z","timestamp":1423290020000},"page":"55-63","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS)"],"prefix":"10.1007","volume":"50","author":[{"given":"Pu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,8]]},"reference":[{"key":"8466_CR1","doi-asserted-by":"crossref","first-page":"5741","DOI":"10.1182\/blood-2011-07-325217","volume":"118","author":"VK Rao","year":"2011","unstructured":"Rao VK, Oliveira JB (2011) How I treat autoimmune lymphoproliferative syndrome. Blood 118:5741\u20135751","journal-title":"Blood"},{"key":"8466_CR2","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0022-3476(67)80262-2","volume":"70","author":"VC Canale","year":"1967","unstructured":"Canale VC, Smith CH (1967) Chronic lymphadenopathysimulating malignant Lymphoma.J. Paediatr 70:891\u2013899","journal-title":"Paediatr"},{"key":"8466_CR3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1172\/JCI115867","volume":"90","author":"MC Sneller","year":"1992","unstructured":"Sneller MC, Straus SE, Jaffe ES et al (1992) A novel lymphoproliferative\u2044autoimmune syndrome resembling murinelpr\u2044gld disease. J Clin Invest 90:334\u2013341","journal-title":"J Clin Invest"},{"key":"8466_CR4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/356314a0","volume":"356","author":"R Watanabe-Fukunaga","year":"1992","unstructured":"Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Naqata S (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314\u2013317","journal-title":"Nature"},{"key":"8466_CR5","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/0092-8674(94)90375-1","volume":"76","author":"T Takahashi","year":"1994","unstructured":"Takahashi T, Tanaka M, Brannan CI et al (1994) Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969\u2013976","journal-title":"Cell"},{"key":"8466_CR6","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1126\/science.7539157","volume":"268","author":"F Rieux-Laucat","year":"1995","unstructured":"Rieux-Laucat F, Le Deist F, Hivroz C et al (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347\u20131349","journal-title":"Science"},{"key":"8466_CR7","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/0092-8674(95)90013-6","volume":"81","author":"GH Fisher","year":"1995","unstructured":"Fisher GH, Rosenberg FJ, Straus SE et al (1995) Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81:935\u2013946","journal-title":"Cell"},{"key":"8466_CR8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2141.2006.05993.x","volume":"133","author":"A Worth","year":"2006","unstructured":"Worth A, Thrasher AJ H, Gaspar HB (2006) Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype. Br J Haematol 133:124\u2013140","journal-title":"Br J Haematol"},{"key":"8466_CR9","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.3324\/haematol.2012.070524","volume":"98","author":"JR Hansford","year":"2013","unstructured":"Hansford JR, Pal M, Poplawski N et al (2013) In utero and early postnatal presentation of autoimmune lymphoproliferative syndrome in a family with a novel FAS mutation. Haematologica 98:e38\u2013e39","journal-title":"Haematologica"},{"key":"8466_CR10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10067-003-0830-2","volume":"23","author":"M Deutsch","year":"2004","unstructured":"Deutsch M, Tsopanou E, Dourakis SP (2004) The autoimmune lymphoproliferative syndrome (Canale-Smith) in adulthood. Clin Rheumatol 23:43\u201344","journal-title":"Clin Rheumatol"},{"key":"8466_CR11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00128072-200305030-00005","volume":"5","author":"V Werff der","year":"2003","unstructured":"der Werff V, ten Bosch J (2003) Autoimmune lymphoproliferative syndrome: etiology, diagnosis, and management. Paediatr Drugs 5:185\u2013193","journal-title":"Paediatr Drugs"},{"key":"8466_CR12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2141.2009.07991.x","volume":"148","author":"DT Teachey","year":"2010","unstructured":"Teachey DT, Seif AE, Grupp SA (2010) Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS). Br J Haematol 148:205\u2013216","journal-title":"Br J Haematol"},{"key":"8466_CR13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/00008480-199912000-00009","volume":"11","author":"CE Jackson","year":"1999","unstructured":"Jackson CE, Puck JM (1999) Autoimmune lymphoproliferative syndrome, a Disorder of apoptosis. Curr Opin Pediatr 11:521\u2013527","journal-title":"Curr Opin Pediatr"},{"key":"8466_CR14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V98.1.194","volume":"98","author":"SE Straus","year":"2001","unstructured":"Straus SE, Jaffe ES, Puck JM et al (2001) The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 98:194\u2013200","journal-title":"Blood"},{"key":"8466_CR15","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2004-09-3542","volume":"105","author":"DT Teachey","year":"2005","unstructured":"Teachey DT, Manno CS, Axsom KM et al (2005) Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood 105:2443\u20132448","journal-title":"Blood"},{"key":"8466_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0609.2011.01617.x","volume":"87","author":"M Madkaikar","year":"2011","unstructured":"Madkaikar M, Mhatre S, Gupta M, Ghosh K (2011) Advances in autoimmune lymphoproliferative syndromes. Eur J Haematol 87:1\u20139","journal-title":"Eur J Haematol"},{"key":"8466_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOP.0b013e32834ea739","volume":"24","author":"DT Teachey","year":"2012","unstructured":"Teachey DT (2012) New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome. Curr Opin Pediatr 24:1\u20138","journal-title":"Curr Opin Pediatr"},{"key":"8466_CR18","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1182\/blood-2010-04-280347","volume":"116","author":"JB Oliveira","year":"2010","unstructured":"Oliveira JB, Bleesing JJ, Dianzani U et al (2010) Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome: report from the 2009 NIH International Workshop. Blood 116:e35\u2013e40","journal-title":"Blood"},{"key":"8466_CR19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1006\/clim.2002.5225","volume":"104","author":"JJ Bleesing","year":"2002","unstructured":"Bleesing JJ, Brown MR, Novicio C (2002) A composite picture of TcR alpha\/ beta (+) CD4(\u2212)CD8(+) T Cells (alpha\/beta-DNTCs) in humans with autoimmune lymphoproliferative syndrome. Clin Immunol 104:21\u201330","journal-title":"Clin Immunol"},{"key":"8466_CR20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1006\/clim.2001.5069","volume":"100","author":"JJ Bleesing","year":"2001","unstructured":"Bleesing JJ, Brown MR, Dale JK et al (2001) TcR-alpha\/beta (+) CD4(\u2212)CD8(+)T cells in humans with the autoimmune lymphoproliferative syndrome express a novel CD45 isoform that is analogous to murine B220 and represents a marker of altered O-glycan biosynthesis. Clin Immunol 100:314\u2013324","journal-title":"Clin Immunol"},{"key":"8466_CR21","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2004-07-2583","volume":"105","author":"K Fischer","year":"2005","unstructured":"Fischer K, Voelkl S, Heymann J et al (2005) Isolation and characterization of human antigen-specific TCR alpha beta\u2009+\u2009CD4(\u2212)CD8(+) double-negative regulatory T cells. Blood 105:2828\u20132835","journal-title":"Blood"},{"key":"8466_CR22","doi-asserted-by":"crossref","unstructured":"Muppidi J, Porter M, Siegel RM (2004) Measurement of apoptosis and other forms of cell death. Curr Protoc Immunol. Chapter 3:Unit 3.17","DOI":"10.1002\/0471142735.im0317s59"},{"key":"8466_CR23","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMoa040036","volume":"351","author":"E Holzelova","year":"2004","unstructured":"Holzelova E, Vonarbourg C, Stolzenberg MC et al (2004) Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med 351:1409\u20131418","journal-title":"N Engl J Med"},{"key":"8466_CR24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.7326\/0003-4819-130-7-199904060-00020","volume":"130","author":"SE Straus","year":"1999","unstructured":"Straus SE, Sneller M, Lenardo MJ, Puck JM, Strober W (1999) An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med 130:591\u2013601","journal-title":"Ann Intern Med"},{"key":"8466_CR25","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jaci.2009.12.983","volume":"125","author":"I Caminha","year":"2010","unstructured":"Caminha I, Fleisher TA, Hornung RL et al (2010) Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol 125:946\u2013949","journal-title":"J Allergy Clin Immunol"},{"key":"8466_CR26","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.clinbiochem.2012.01.016","volume":"45","author":"RA Bowen","year":"2012","unstructured":"Bowen RA, Dowdell KC, Dale JK et al (2012) Elevated vitamin B12 levels in autoimmune lymphoproliferative syndrome attributable to elevated haptocorrin in lymphocytes. Clin Biochem 45:490\u2013492","journal-title":"Clin Biochem"},{"key":"8466_CR27","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1182\/blood-2011-04-347641","volume":"118","author":"B Neven","year":"2011","unstructured":"Neven B, Magerus-Chatinet A, Florkin B et al (2011) A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood 118:4798\u20134807","journal-title":"Blood"},{"key":"8466_CR28","first-page":"538","volume":"91","author":"MF Campagnoli","year":"2006","unstructured":"Campagnoli MF, Garbarini L, Quarello P et al (2006) The broad spectrum of autoimmune lymphoproliferative disease:molecular bases, clinical features and long-term follow-up in 31 patients. Haematologica 91:538\u2013541","journal-title":"Haematologica"},{"key":"8466_CR29","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2013-10-535393","volume":"123","author":"S Price","year":"2014","unstructured":"Price S, Shaw PA, Seitz A et al (2014) Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood 123:1989\u20131999","journal-title":"Blood"},{"key":"8466_CR30","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0031-3955(05)70272-8","volume":"47","author":"JJ Bleesing","year":"2000","unstructured":"Bleesing JJ, Straus SE, Fleisher TA (2000) Autoimmune lymphoproliferative syndrome. A human disorder of abnormal lymphocyte survival. Pediatr Clin North Am 47:1291\u20131310","journal-title":"Pediatr Clin North Am"},{"key":"8466_CR31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/10245330500329094","volume":"11","author":"VK Rao","year":"2006","unstructured":"Rao VK, Straus SE (2006) Causes and consequences of the autoimmune lymphoproliferative syndrome. Hematology 11:15\u201323","journal-title":"Hematology"},{"key":"8466_CR32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature01063","volume":"419","author":"HJ Chun","year":"2002","unstructured":"Chun HJ, Zheng L, Ahmad M et al (2002) Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 419:395\u2013399","journal-title":"Nature"},{"key":"8466_CR33","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s11882-014-0462-4","volume":"14","author":"S Shah","year":"2014","unstructured":"Shah S, Wu E, Rao VK, Tarrant TK (2014) Autoimmune lymphoproliferative syndrome: an update and review of the literature. Curr Allergy Asthma Rep 14:462","journal-title":"Curr Allergy Asthma Rep"},{"key":"8466_CR34","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s10875-012-9731-y","volume":"32","author":"MG Simesen de Bielke","year":"2012","unstructured":"Simesen de Bielke MG, Yancoski J, Rocco C et al (2012) A missense mutation in the extracellular domain of Fas: the most common change in Argentinean patients with autoimmune lymphoproliferative syndrome represents a founder effect. J Clin Immunol 32:1197\u20131203","journal-title":"J Clin Immunol"},{"key":"8466_CR35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1744-313X.2011.01005.x","volume":"38","author":"H Tadaki","year":"2011","unstructured":"Tadaki H, Saitsu H, Kanegane H et al (2011) Exonic deletion of CASP10 in a patient presenting with systemic juvenile idiopathic arthritis, but not with autoimmune lymphoproliferative syndrome type IIa. Int J Immunogenet 38:287\u2013293","journal-title":"Int J Immunogenet"},{"key":"8466_CR36","doi-asserted-by":"crossref","first-page":"e68045","DOI":"10.1371\/journal.pone.0068045","volume":"8","author":"M Aric\u00f2","year":"2013","unstructured":"Aric\u00f2 M, Boggio E, Cetica V et al (2013) Variations of the UNC13D gene in patients with autoimmune lymphoproliferative syndrome. PLoS One 8:e68045","journal-title":"PLoS One"},{"key":"8466_CR37","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1182\/blood-2010-08-301515","volume":"117","author":"M Takagi","year":"2011","unstructured":"Takagi M, Shinoda K, Piao J et al (2011) Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. Blood 117:2887\u20132890","journal-title":"Blood"},{"key":"8466_CR38","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1182\/blood-2010-07-295501","volume":"117","author":"JE Niemela","year":"2011","unstructured":"Niemela JE, Lu L, Fleisher TA et al (2011) Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. Blood 117:2883\u20132886","journal-title":"Blood"},{"key":"8466_CR39","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1182\/blood-2012-08-452425","volume":"121","author":"Q Guo","year":"2013","unstructured":"Guo Q, Zhang J, Li J et al (2013) Forced miR-146a expression causes autoimmune lymphoproliferativesyndrome in mice via downregulation of Fas in germinal center B cells. Blood 121:4875\u20134883","journal-title":"Blood"},{"key":"8466_CR40","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.1182\/blood-2010-01-263145","volume":"115","author":"KC Dowdell","year":"2010","unstructured":"Dowdell KC, Niemela JE, Price S et al (2010) Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. Blood 115:5164\u20135169","journal-title":"Blood"},{"key":"8466_CR41","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1073\/pnas.0702975104","volume":"104","author":"JB Oliveira","year":"2007","unstructured":"Oliveira JB, Bidere N, Niemela JE et al (2007) NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci U S A 104:8953\u20138958","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8466_CR42","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/blood.V89.8.2871","volume":"89","author":"U Dianzani","year":"1997","unstructured":"Dianzani U, Bragardo M, DiFranco D et al (1997) Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity\/lymphoproliferation. Blood 89:2871\u20132879","journal-title":"Blood"},{"key":"8466_CR43","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1182\/blood.V95.10.3176","volume":"95","author":"U Ramenghi","year":"2000","unstructured":"Ramenghi U, Bonissoni S, Migliaretti G et al (2000) Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer. Blood 95:3176\u20133182","journal-title":"Blood"},{"key":"8466_CR44","first-page":"2976","volume":"119","author":"AL Snow","year":"2009","unstructured":"Snow AL, Marsh RA, Krummey SM et al (2009) Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency. J Clin Invest 119:2976\u20132989","journal-title":"J Clin Invest"},{"key":"8466_CR45","doi-asserted-by":"crossref","first-page":"e1440","DOI":"10.1542\/peds.2012-2748","volume":"132","author":"A Rudman Spergel","year":"2013","unstructured":"Rudman Spergel A, Walkovich K, Price S et al (2013) Autoimmune lymphoproliferative syndrome misdiagnosed as hemophagocytic lymphohistiocytosis. Pediatrics 132:e1440\u2013e1444","journal-title":"Pediatrics"},{"key":"8466_CR46","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s12185-011-0877-9","volume":"93","author":"K Nomura","year":"2011","unstructured":"Nomura K, Kanegane H, Otsubo K et al (2011) Autoimmune lymphoproliferative syndrome mimicking chronic active Epstein-Barr virus infection. Int J Hematol 93:760\u2013764","journal-title":"Int J Hematol"},{"key":"8466_CR47","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/pbc.21965","volume":"52","author":"VK Rao","year":"2009","unstructured":"Rao VK, Price S, Perkins K et al (2009) Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatric Blood Cancer 52:847\u2013852","journal-title":"Pediatric Blood Cancer"},{"key":"8466_CR48","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2141.2009.07715.x","volume":"146","author":"N Cooper","year":"2009","unstructured":"Cooper N, Davies EG, Thrasher AJ (2009) Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Haematol 146:120\u2013122","journal-title":"Br J Haematol"},{"key":"8466_CR49","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2014-02-553834","volume":"124","author":"B Neven","year":"2014","unstructured":"Neven B, Bruneau J, Stolzenberg MC et al (2014) Defective anti-polysaccharide response and splenic marginal zone disorganization in ALPS patients. Blood 124:1597\u20131609","journal-title":"Blood"},{"key":"8466_CR50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12288-011-0058-2","volume":"27","author":"S Arora","year":"2011","unstructured":"Arora S, Singh N, Chaudhary GK, John MJ (2011) Autoimmune lymphoproliferative syndrome: response to mycophenolate mofetil and pyrimethamine\/sulfadoxine in a 5-year-old child. Indian J Hematol Blood Transfus 27:101\u2013103","journal-title":"Indian J Hematol Blood Transfus"},{"key":"8466_CR51","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2141.2009.07595.x","volume":"145","author":"DT Teachey","year":"2009","unstructured":"Teachey DT, Greiner R, Seif A et al (2009) Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol 145:101\u2013106","journal-title":"Br J Haematol"},{"key":"8466_CR52","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/pbc.23144","volume":"57","author":"R Bajwa","year":"2011","unstructured":"Bajwa R, Savelli S, Gross T (2011) Pentostatin for treatment of refractory autoimmune lymphoproliferative syndrome. Pediatr Blood Cancer 57:336\u2013337","journal-title":"Pediatr Blood Cancer"},{"key":"8466_CR53","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2141.2005.05496.x","volume":"129","author":"VK Rao","year":"2005","unstructured":"Rao VK, Dugan F, Dale JK et al (2005) Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol 129:534\u2013538","journal-title":"Br J Haematol"},{"key":"8466_CR54","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1182\/blood-2006-04-020610","volume":"108","author":"P Bob\u00e9","year":"2006","unstructured":"Bob\u00e9 P, Bonardelle D, Benihoud K et al (2006) Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL\/lpr mice. Blood 108:3967","journal-title":"Blood"},{"key":"8466_CR55","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.exphem.2008.12.002","volume":"37","author":"KC Dowdell","year":"2009","unstructured":"Dowdell KC, Pesnicak L, Hoffmann V et al (2009) Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas deficient MRL\/lpr(\u2212\/\u2212) murine model of autoimmune lymphoproliferative syndrome (ALPS). Exp Hematol 37:487\u2013494","journal-title":"Exp Hematol"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-015-8466-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-015-8466-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-015-8466-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T19:16:02Z","timestamp":1598728562000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-015-8466-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,8]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["8466"],"URL":"https:\/\/doi.org\/10.1007\/s12016-015-8466-y","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,8]]}}}